Back to top

Analyst Blog

Apart from obesity drug Qsymia, VIVUS, Inc.’s (VVUS - Analyst Report) portfolio consists of another approved product, Stendra (trade name: Spedra in Europe), for erectile dysfunction (ED). Stendra, a phosphodiesterase type 5 (PDE5) inhibitor, received marketing approval in the U.S. in Apr 2012 and in the EU in Jun 2013.

VIVUS has entered into a license and commercialization agreement with Menarini. As per the terms of the agreement, Menarini will get the rights to Stendra in more than 40 European countries, apart from Australia and New Zealand.

VIVUS has entered into an agreement for Stendra with Auxilium Pharmaceuticals, Inc. (AUXL - Analyst Report).

As per the terms of the agreement, Auxilium will get the rights to Stendra in the U.S. and Canada. In exchange VIVUS will get an upfront payment, milestone and other payments totaling approximately $300 million, depending upon certain pre-specified criteria.

VIVUS and Auxilium also entered into a supply agreement for Stendra, according to which VIVUS will supply the product to the latter.

The partnership on Stendra will not only boost VIVUS’ balance sheet but also go a long way in removing uncertainties related to the drug’s launch in the U.S. scheduled later this year.

In Jul 2013, VIVUS had announced encouraging data from a multi-center, placebo-controlled study (TA-501) evaluating the efficacy of Stendra in men suffering from ED.

The study enrolled 440 patients with mild-to-severe ED with or without diabetes. Data from the study revealed that on an average Stendra was effective after 10 minutes and 12 minutes of taking the 200 mg and 100 mg formulation of the drug, respectively.

According to the company, ED therapies recorded combined sales of over $2.9 billion in 2012 in the U.S. The ED market is expected to grow further in the coming years.

Currently approved PDE5 inhibitors including Viagra and Cialis are recommended for ingestion one to two hours prior to sexual activity or daily. We believe Stendra’s fast action could help the drug gain share.

VIVUS currently carries a Zacks Rank #3 (Hold). Currently, companies like Roche (RHHBY - Analyst Report) and Isis Pharmaceuticals, Inc. (ISIS - Analyst Report) look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%